Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | CSF1R | P07333 | 7/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059980 | 0.92 | CSF1R (0.47) | KDRABL1AXLSRCCSF1R | |
| SCHEMBL5052271 | 0.89 | KDR (0.52) | KDRABL1AXLSRCCSF1R | |
| SCHEMBL5056625 | 0.89 | ABL1 (0.46) | KDRABL1AXLSRCCSF1R | |
| SCHEMBL5062413 | 0.89 | KDR (0.55) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5059967 | 0.87 | KDR (0.60) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5054737 | 0.86 | KDR (0.57) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5054949 | 0.85 | KDR (0.56) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5056645 | 0.85 | ABL1 (0.49) | KDRABL1AXLSRCCSF1R | |
| SCHEMBL5062168 | 0.84 | KDR (0.54) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5054668 | 0.84 | KDR (0.55) | KDRAXLCSF1RPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KDR 41/4885ABL1 20/4885AXL 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.